期刊文献+

18F-FDG PET/CT联合改良国际预后指标(NCCN-IPI)对弥漫大B细胞淋巴瘤预后评估的价值分析 被引量:2

Prognostic value of 18F-FDG PET/CT combined with an enhanced international prognostic index(NCCN-IPI)in diffuse large B cell lymphoma
原文传递
导出
摘要 目的探讨改良国际预后指标(NCCN-IPI)对治疗结束后18F-FDG PET/CT评价为阴性的弥漫大B细胞淋巴瘤(DLBCL)患者的预后分层价值。方法回顾性分析2013年4月至2017年8月在苏州大学附属第一医院经过6~8周期R-CHOP类方案化疗后,并经18F-FDG PET/CT评价为阴性的60例DLBCL患者的临床资料,其中男性28例、女性32例,中位年龄51岁(16~81岁)。采用NCCN-IPI进行危险度分层,采用Log-rank检验比较各组间无进展生存(PFS)期和总生存(OS)期的差异。结果所有患者2年PFS率为83.33%(50/60),2年OS率为96.67%(58/60)。根据NCCN-IPI评分,低危组占35.0%(21/60),低中危组占41.7%(25/60),中高危组占18.3%(11/60),高危组占5.0%(3/60)。低危组与其他组间PFS差异有统计学意义(P=0.0272、0.0143、<0.0001),高危组与其他组间OS差异有统计学意义(P=0.0098、0.0166、0.0045),余各组间PFS及OS差异无统计学意义(均P>0.05)。结论应用NCCN-IPI可以对治疗结束后18F-FDG PET/CT评价为阴性的DLBCL患者进行进一步的预后分层。 Objective To investigate the prognostic stratification value of an enhanced international prognostic index(NCCN-IPI)in patients with diffuse large B-cell lymphoma(DLBCL)who are negative at the end of treatment with positron emission tomography computed tomography(PET/CT).Methods A retrospective analysis was conducted on 60 patients with DLBCL from April 2013 to August 2017 in the first affiliated hospital of Soochow university.There were 28 males and 32 females,with a median age of 51 years(16-81 years).Baseline characteristics were collected from all the patients who underwent six-to eight-cycle R-CHOP regimen chemotherapy and were negative by 18F-FDG PET/CT.The risk stratification was performed by NCCN-IPI,Log-rank test was used for comparison of the differences in progression-free survival(PFS)and overall survival(OS)between groups.Results The patients featured a median follow-up of 34 months(14-69 months).The two-year PFS and OS rates reached 83.33%(50/60)and 96.67%(58/60),respectively.On the basis of NCCN-IPI risk categorization,35.0%(21/60),41.7%(25/60),18.3%(11/60)and 5.0%(3/60)patients belonged to the low-,low-intermediate-,high-intermediate-,and high-risk subgroups,respectively.A statistically significant difference was observed in the PFS between the low-risk group and the other groups(P=0.0272,0.0143,<0.0001)and in the OS between the high-risk group and the other groups(P=0.0098,0.0166,0.0045).The difference between the PFS and OS of other components showed no statistical significance(all P>0.05).Conclusion Further prognostic stratification can be performed by NCCN-IPI in patients with DLBCL who are negative at the end of treatment by PET/CT.
作者 赵曼 吴翼伟 Zhao Man;Wu Yiwei(Department of Nuclear Medicine,the First Affiliated Hospital of Soochow University,Suzhou 215000,China)
出处 《国际放射医学核医学杂志》 2019年第5期427-431,共5页 International Journal of Radiation Medicine and Nuclear Medicine
关键词 弥漫大B细胞淋巴瘤 正电子发射断层显像计算机体层摄影术 国际预后指数 Diffuse large B-cell lymphoma Positron emission tomography computed tomography national comprehensive cancer network-international prognostic index
  • 引文网络
  • 相关文献

参考文献3

二级参考文献52

  • 1Pfreundschuh M, Triimper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) Group. Lancet Oncol, 2006, 7 : 379-391.
  • 2Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol, 2008, 9: 105- 116.
  • 3Coiffier B, Thieblemont C, Neste EVD, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 2010, 116: 2040-2045.
  • 4Thomas A, Gingrich R, DSmith BJ, et al. 18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of ' indeterminate' reports. Leuk Lymphoma, 2010, 51 : 439-446.
  • 5Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emisstion tomography for response assessment of lymphoma:consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol, 2007, 25: 571-578.
  • 6Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol, 2007, 25: 579-556.
  • 7Han HS, Escalon MP, Hsiao B, et al. High incidence of falsepositive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol, 2009, 20: 309-318.
  • 8Hohe H, Bogsrud T, Leppa S, et al. 18F-FDG PET/CT after intensified chemo-immunotherapy in diffuse large B-cell lymphoma aged 18-65 with aalPI 2-3 positive or indeterminate lesions are often false-positive: a Nordic phase Ⅱ substudy. J Clin Oncol, 29: 2011 ( suppl ; abstr el 8519 ).
  • 9Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin' s lymphoma. J Clin Oneol, 2005, 23: 4643-4651.
  • 10Hutchings M, Loft A, Hansen M, et al. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol, 2006, 24:146-150.

共引文献31

同被引文献11

引证文献2

二级引证文献1

;
使用帮助 返回顶部